Other substances

Tinzaparin

anticoagulant drug

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
7
 Clinical trials

General information

low molecular weight heparin 

 

Supporting references

Link Tested on Impact factor Notes Publication date
SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins.
Spike protein Preprint 		in vitro Apr/29/2020

AI-suggested references

Link Publication date
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Nov/23/2020
Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study
Apr/07/2022
The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
Nov/17/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05036824 Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients Recruiting Oct/01/2021 Apr/30/2022
  • Alternative id - 18634/23-7-2021 pend. aprooval
  • Interventions - Drug: tinzaparin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University Hospital of Patras, Patras, Achaia, Greece|Evangelismos General Hospital, Athens, Attica, Greece|General Hopital Elpis, Athens, Attica, Greece|University General Hospital of Ioannina, Ioannina, Epirus, Greece|General Hospital of Kerkira "Ag. Irini", Korfu, Ionian Islands, Greece|General Hospital of Kozani "Mamatsio", Kozáni, Macedonia, Greece|Genereal Hospital of Patras "Ag. Andreas", Patras, Peloponnese, Greece
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of thrombotic events|Incidence of bleeding events|WHO progression scale|Length of hospital stay
NCT04483960 Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial Recruiting Phase 3 Jul/28/2020 Dec/31/2022
  • Alternative id - ERM 62646-A
  • Interventions - Drug: Nafamostat Mesilate|Biological: Hyperimmune Globulin|Drug: Enoxaparin|Drug: Dalteparin|Drug: Tinzaparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Calvary Public Bruce Hospital, Bruce, Australian Capital Territory, Australia|The Canberra Hospital, Canberra, Australian Capital Territory, Australia|Armidale Hospital, Armidale, New South Wales, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|The Sutherland Hospital, Caringbah, New South Wales, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Griffith Base Hospital, Griffith, New South Wales, Australia|Hornsby Ku-Ring Gai Hospital, Hornsby, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Ballarat Health Services, Ballarat Central, Victoria, Australia|St John of God Ballarat Hospital, Ballarat, Victoria, Australia|Bendigo Health, Bendigo, Victoria, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Monash Health, Clayton, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Frankston Hospital - Penninsula Health, Frankston, Victoria, Australia|Peninsula Private Hospital, Frankston, Victoria, Australia|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Western Health, St Albans, Victoria, Australia|Latrobe Regional Hospital, Traralgon, Victoria, Australia|West Gippsland Hospital, Warragul, Victoria, Australia|Albury Wodonga Health, Wodonga, Victoria, Australia|Rockingham General Hospital, Cooloongup, Western Australia, Australia|Joondalup Health Campus, Joondalup, Western Australia, Australia|Armadale Health Service, Mount Nasura, Western Australia, Australia|Fiona Stanley Hospita, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Death from any cause or requirement of new intensive respiratory support (invasive or non-invasive ventilation) or vasopressor/inotropic support.|Time to clinical recovery|WHO 8-point ordinal outcome scale|All-cause mortality|Days alive and free of hospital|Days alive and free of invasive or non-invasive ventilation|Shortness of breath|Quality of life|Antiviral domain-specific outcome: Viral clearance|Antiviral domain-specific outcome: Viral load|Antiviral domain-specific outcome: Safety (Liver enzymes)|Antiviral domain-specific outcome: Safety (potassium)|Antiviral domain-specific outcome: Safety (sodium)|Antiviral domain-specific outcome: Safety (bleeding)|Antiviral domain-specific outcome: Safety (thrombophlebitis)|Antiviral domain-specific outcome: serious adverse reactions|Antibody domain-specific outcome: Serious treatment-related adverse events|Antibody domain-specific outcome: Haemolysis|Antibody domain-specific outcome: Confirmed arterial thrombosis|Antibody domain-specific outcome: Confirmed venous thrombosis|Anticoagulation domain-specific outcome: Confirmed deep venous thrombosis|Anticoagulation domain-specific outcome: Confirmed pulmonary embolus|Anticoagulation domain-specific outcome: Confirmed acute myocardial infarction|Anticoagulation domain-specific outcome: Confirmed ischemic cerebrovascular event|Anticoagulation domain-specific outcome: Major bleeding|Anticoagulation domain-specific outcome: Clinically relevant non-major bleeding|Anticoagulation domain-specific outcome: Heparin-induced thrombocytopenia (HIT)|Anticoagulation domain-specific outcome: Other confirmed thrombotic event
NCT04593654 Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients Completed Mar/01/2020 Oct/15/2020
  • Alternative id - Thromboprophylaxis COVID-19
  • Interventions - Drug: Dose of tinzaparin or dalteparin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Södersjukhuset, Stockholm, Sweden
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 257
  • Age - Child, Adult, Older Adult
  • Outcome measures - 28-day mortality|Incidence of thromboembolic events|Incidence of bleeding events|ICU-free days alive from ICU-admission|90-day mortality
NCT04412304 Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients Completed Mar/06/2020 May/28/2020
  • Alternative id - Anticoagulant therapy Covid-19
  • Interventions - Drug: Dose of Tinzaparin or Dalteparin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - South General Hospital, Stockholm, Stockholms Län, Sweden
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 166
  • Age - Child, Adult, Older Adult
  • Outcome measures - 28-days ICU mortality|Incidence of thromboembolic events|Incidence of bleeding events|ICU-free days alive from ICU-admission.
NCT04808882 ANTIcoagulation in Severe COVID-19 Patients Recruiting Phase 2 Apr/14/2021 Feb/01/2022
  • Alternative id - APHP201624|2020-A03531-38
  • Interventions - Drug: Tinzaparin, Low dose prophylactic anticoagulation|Drug: Tinzaparin, High dose prophylactic anticoagulation|Drug: Tinzaparin,Therapeutic anticoagulation
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Henri Mondor Hospital, Créteil, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 353
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|Number of days to clinical improvement|Score on WHO Ordinal Scale|Number of days alive and free from supplemental oxygen at Day-28|Proportion of patients needing intubation at Day-28|Number of days alive and free from invasive mechanical ventilation at Day-28|Number of days alive and free from vasopressors at Day-28|Length of intensive care unit stay|Length of hospital stay|Quality of life and disability at assessed using a quality of life questionnaire|All-cause deaths|Proportion of patients with at least one thrombotic event at Day-28|D-dimers|Proportion of patients with at least one major bleeding event (MBE) at Day-28|Proportion of patients with at least one life-threatening bleeding event at Day-28|Proportion of patients with any bleeding event at Day-28|Proportion of patients with Heparin Induced Thrombocytopenia (HIT) at Day-28|7-points ordinal scale|Sepsis-Induced Coagulopathy Score (SCS)
NCT04344756 Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Not yet recruiting Phase 2 Apr/20/2020 Sep/30/2020
  • Alternative id - APHP200389-6
  • Interventions - Drug: Tinzaparin or unfractionated heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Réanimation hôpital Louis Mourier, Colombes, Hauts De Seine, France|réanimation hôpital Cochin, Paris, France|Médecine vasculaire, Hôpital Européen Georges Pompidou, Paris, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 808
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale ≤5|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events
NCT04730856 Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID) Completed Not Applicable Feb/01/2021 Dec/20/2021
  • Alternative id - PROTHROMCOVID
  • Interventions - Drug: Tinzaparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario del Vinalopó, Alicante, Spain|Hospital Clínic Barcelona, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital de Emergencias Enfermera Isabel Zendal, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Álvaro Cunqueiro, Vigo, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  • Enrollment - 311
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Reduction of suspicion of systemic thrombotic symptomatic events|Use of Mechanical ventilation|Progression on the WHO Progression Scale during follow-up.|Overall survival at 30 days.|Length of hospital stay (days)|Length of ICU stay (days)|Number of bleedings and adverse reactions
Export (.csv)